Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

achieve the Abbott milestones, and expenses for Regulus, which began in September 2007. On a GAAP basis, Isis' operating expenses for the three and six months ended June 30, 2008 were $36.1 million and $66.3 million, respectively, compared to $23.5 million and $46.8 million for the same periods in 2007, including non-cash compensation expense related to stock options of $4.0 million and $7.8 million for the three and six months ended June 30, 2008 and $2.4 million and $4.8 million for the same periods in 2007.

Net Loss

Isis' net loss for the three and six months ended June 30, 2008 was $2.2 million and $6.5 million, respectively, compared to $11.0 million and $24.0 million for the same periods in 2007. Isis' net loss for the first half of 2008 was lower than the first half of 2007 primarily due to the decrease in the Company's loss from operations.

Balance Sheet

As of June 30, 2008, Isis had cash, cash equivalents and short-term investments of $537.0 million compared to $193.7 million at December 31, 2007. In 2008, Isis has received a significant amount of cash from its partners including:
-- $325.0 million from Genzyme

-- $40.5 million from Abbott

-- $20.0 million from GSK

As of June 30, 2008, Isis had consolidated working capital of $428.1 million compared to $145.1 million at December 31, 2007. The cash Isis received in the first half of 2008 primarily led to the increase in Isis' consolidated working capital, offset by $68.9 million of deferred revenue from Genzyme and GSK that is included in current liabilities.

Based on Isis' existing and committed cash, not including the cash Isis could receive from Abbott if Abbott completes its purchase of Ibis, Isis remains on track to meet its cash guidance with a 2008 year end cash balance greater than $450 million, which the Company expects will last for at least five years.

Ibis Biosciences, Inc.

Ibis' revenue for the three and six month
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for odour control projects in North America ... Asia . "Bidding activity in 2015 continues to ... "After a high volume year for bidding in 2014, we are ... The recent orders reflect the organization,s renewed focus on select market ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Thingee to present at 11th Annual Synergistix Users Conference 2
... BOSTON, Jan. 10, 2011 Entrega, Inc., a ... announced its formation by Enlight Biosciences, a Boston-based ... leading global pharmaceutical companies. As part of its ... spatially-directed proprietary drug delivery platform to create orally ...
... win. The professor of biotechnology at Delft University of ... in Rice University,s Matteo Pasquali. Together with ... (CNRS), the University of Bordeaux, France, and Vrije University, ... a long-standing controversy in the field of polymer dynamics: ...
... The Pittsburgh Life Sciences Greenhouse (PLSG), the organization ... growth programs to the region,s life sciences enterprises, issued ... John W. Manzetti announcing the first close of the ... Fund) at $5 million. The Accelerator Fund ...
Cached Biology Technology:New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 2New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 3Bendy tubes get around 2Bendy tubes get around 3Pittsburgh Life Sciences Greenhouse Announces the First Close of the PLSG Accelerator Fund LLC at $5 Million 2
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... PASADENA, Calif.The frontal lobes are the largest part of ... that expanded most during human evolution. Damage to the ... eyescan result in profound impairments in higher-level reasoning and ... parts of the frontal lobes do, neuroscientists at the ...
... London and the University of Exeter Medical School has identified ... responsible for controlling eye muscles, resulting in movement disorders such ... could provide the key to reversing the condition and unlocking ... body. The research is published in Proceedings of ...
... Life in the world,s oceans faces far greater change and ... human history, a team of the world,s leading marine scientists ... Germany, Panama, Norway and the UK have compared events which ... what is observed to be taking place in the seas ...
Cached Biology News:Thinking and choosing in the brain 2Thinking and choosing in the brain 3Research identifies mechanism responsible for eye movement disorder 2Research identifies mechanism responsible for eye movement disorder 3Sea life 'facing major shock' 2Sea life 'facing major shock' 3
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Affinity Purified Anti-Human NP-1...
Biology Products: